You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MET mutation

Showing 1 - 25 of 4,250
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Endometrial Cancer Recurrent Trial in Tainan (Crizotinib 250 MG)

Recruiting
  • Endometrial Cancer Recurrent
  • Crizotinib 250 MG
  • Tainan, Taiwan
    National Cheng Kung University Hospital
Jun 6, 2022

NSCLC Trial in Guangzhou (PLB1001)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Aug 15, 2023

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain

Completed
  • Metastatic Non-Small Cell Lung Cancer
  • East Hanover, New Jersey
    18 Novartis Investigative Sites in the US
Dec 29, 2022

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer Trial in San Francisco (Capmatinib, Trametinib)

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer
  • San Francisco, California
    University of California San Francisco
Aug 15, 2022

Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

Recruiting
  • Non-Small Cell Lung Carcinoma
  • Capmatinib 150 mg
  • Capmatinib 200 mg
  • Guwahati, Assam, India
  • +7 more
Dec 19, 2022

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

Lung Sarcomatoid Carcinoma Trial in Beijing, Shanghai (Savolitinib)

Active, not recruiting
  • Lung Sarcomatoid Carcinoma
  • Beijing, Beijing, China
  • +1 more
Nov 29, 2021

NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100

Not yet recruiting
  • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
  • MCLA-129: 1500mg or 2000mg IV Q2W
  • Befotertinib: 75 mg or 100 mg Po QD
  • Bengbu, Anhui, China
  • +2 more
Aug 28, 2023

NSCLC (NSCLC) Trial in China (Capmatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Xiamen, Fujian, China
  • +18 more
Jan 27, 2023

NSCLC Trial in United States (capmatinib)

Recruiting
  • Non-small Cell Lung Cancer
  • La Jolla, California
  • +7 more
Oct 5, 2022

c-MET Expression and EGFR Gene Mutation Correlation With

Completed
  • Non-small Cell Lung Cancer Metastatic
  • Non-small Cell Lung Cancer Recurrent
    • Hwasun, Korea, Republic of
      Chonnam National University Hwasun Hospital
    Aug 1, 2021

    Frequency, Clinical Phenotype and Genetic Analysis of Heritable

    Not yet recruiting
    • Renal Tumor Histology
    • +13 more
    • Gene test
    • Shanghai, Shanghai, China
      Ethics Committee of Shanghai Renji Hospital
    Sep 6, 2022

    NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • Kashiwa, Chiba, Japan
    • +3 more
    Jan 31, 2023

    Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification Trial in Korea, Republic of (Tepotinib)

    Recruiting
    • Solid Tumor
    • +2 more
    • Hwasun, Chonnam, Korea, Republic of
    • +21 more
    Nov 30, 2020

    NSCLC Trial in Worldwide (Tepotinib, Gefitinib, Pemetrexed)

    Completed
    Has Results
    • Non-small Cell Lung Cancer
    • Beijing, China
    • +43 more
    Oct 13, 2022

    Solid Tumor, C-Met Mutation-Related Tumors Trial in Shanghai (GST-HG161)

    Unknown status
    • Solid Tumor
    • C-Met Mutation-Related Tumors
    • Shanghai, Shanghai, China
      Shanghai Oriental Hospital
    Jan 10, 2020

    Advanced Malignant Tumor, BRAF Gene Mutation, Metastatic Malignant Tumor Trial in Houston (Crizotinib, Laboratory Biomarker

    Completed
    • Advanced Malignant Neoplasm
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 19, 2021

    NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

    Not yet recruiting
    • Non-Small Cell Lung Cancer Metastatic
    • Seoul, Gangnam-gu, Korea, Republic of
      Samsung Medical Center
    Oct 27, 2023

    NSCLC, Solid Tumor Trial in Boston (Merestinib)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Solid Tumor
    • Boston, Massachusetts
    • +1 more
    Jan 26, 2022

    Negative T790M Mutation and Met Amplification Trial in Beijing (Glumetinib)

    Unknown status
    • Negative T790M Mutation and Met Amplification
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 7, 2020

    Special Drug Use-results Surveillance of Tabrecta Tablets

    Recruiting
    • Non-small Cell Lung Cancer
    • Tabrecta tablets
    • Nagoya, Aichi, Japan
    • +44 more
    Aug 1, 2022

    NSCLC Trial in Chongqing (Aumonertinib 165mg orally once daily and intrathecal chemo with pemetrexed)

    Recruiting
    • Non-small Cell Lung Cancer
    • Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed
    • Chongqing, China
      chongqing University Three Gorges Hospital
    Apr 11, 2023